Oncolytic viruses: the use for cancer immunotherapy
Oncolytic viruses: the use for cancer immunotherapy
Regulatory Affairs Pharma & Biotech ATMP
Monday, 11 September 2023
Lotte Essers & Lieve De Wolf, ATMP experts at QbD Group
Share
\
\
X (Twitter) 
\
\
LinkedIn 
\
\
WhatsApp 
\
\
Copy link 
\
\
Mail
Oncolytic viruses and cellular immunotherapy are creating significant new potential in the fight against cancer. Learn more about the working mechanism, risks, and specific biosafety requirements to be considered for oncolytic viruses.
Play
Oncolytic viruses: the use for cancer immunotherapy | Qbd Group
AI-generated audio
6:57
Immunotherapy has become an important therapeutic alternative to surgery, chemotherapy, and radiation in the fight against cancer. Oncolytic viruses and cellular immunotherapy are creating significant new potential in the fight against cancer.
In this article, we discuss the working mechanism, risks, and specific biosafety requirements to be considered for oncolytic viruses. (For cellular immunotherapy, please see our CAR-T blog post.)
Figure 1 – Evolution of Cancer Pharmacological Treatments at the Turn of the Third Millennium: Falzone Luca, Salomone Salvatore and Libra Massimo, Frontiers in Pharmacology Vol:9 (2018).
What are oncolytic viruses and how do they work?
Viruses are selected based on their inherent oncotropic nature; these viruses are wild-type viruses such as Parvovirus. Other viruses are genetically modified to selectively target tumor cells.
Genetic modification offers several advantages, namely fewer side effects by reducing pathogenicity to non-cancer cells and preventing an antiviral immune response. Oncolytic viruses act on two main mechanisms, tumor cell lysis and/or anti-tumor immunity.
Figure 2 – Oncolytic Viral Therapy and the Immune System: A Double-Edged Sword Against Cancer: Marelli Giulia, Howells Anwen, Lemoine Nicholas R., Wang Yaohe. Frontiers in Immunology, Vol:9 (2018).
How are oncolytic viruses used and what are the advantages?
Oncolytic virotherapy can be seen as the third revolution of tumor treatment after traditional chemotherapy and targeting therapy. OVs are being researched in the treatment of cancer to replace or combine with current treatment options, such as surgery, chemotherapy, hormonal therapy, targeted therapy, or radiation therapy. Those therapies lead to limited long-lasting responses in a large majority of patients with advanced cancer.
Oncolytic virotherapy has many advantages over other tumor immunotherapies, including precise targeting, high lysis efficiency, and low cost. Therapies can be administered by various routes, including direct intra-tumoral administration, which is the most common. Intravenous injection, intraperitoneal, intrathecal, or subcutaneous administration are also possible.
What are the risks and biosafety requirements of oncolytic viruses?
In addition to the benefits, there are some challenges and risks associated with the use of OVs to treat cancer. EudraLex Volume 4 Part IV, GMP for ATMPs, identifies some specific precautions for viral vector production. Specific focus on cross-contamination and segregation is highlighted. In the manufacturing plant a biosafety responsible will be evaluating the safety and precaution measurements of working with viral and genetically modified organisms.
Biosafety levels
When working with potentially infectious agents, safety measures must be taken to reduce the risk of exposure to the laboratorian and contamination of the work environment and community. This is known as biosafety.
The Centers for Disease Control and Prevention (CDC) has specified four different types of biosafety levels (BSL) in the CDC guidance, ranging from BSL-1 to BSL-4. These levels aligned with the containment levels of the HSE (Health and Safety Executive in the UK) and EU regulations (Directive 2000/54/EC).
The level is determined by several factors including infectivity, severity of disease, transmissibility, and the nature of the work performed. The origin of the biological agent and the route of exposure are also important to consider. All these elements combine to determine what BSL is needed.
Figure 3 – The Centers for Disease Control and Prevention (CDC) has specified four different types of biosafety levels (BSL) in the CDC guidance, ranging from BSL-1 to BSL-4.
Each BSL has its own containment controls required for laboratory practices, safety equipment and facility construction. Each microbiology laboratory follows the standard microbiological practices; this is always required. Additional requirements are added depending on the level.
Current therapies and clinical trials
The development of OVs is still in the early stage. Many viral oncolytic therapies are currently in clinical trials, with many showing promising results. Most therapies include the use of genetically engineered OVs alone or in combination with other therapies. Oncolytic virotherapy may be effective as a stand-alone therapy, but combination therapies with radiotherapy, chemotherapy or other immunotherapies are probably necessary to gain full potential. The most widely studied viruses in clinical trials up until now were adenoviruses and herpesviruses.
Imlygic®, was the first oncolytic immunotherapy approved by the FDA and EMA in 2015. The active substance in Imlygic®, talimogene laherparepvec, is derived from a weakened herpes simplex virus 1 (the cold sore virus). This virus has been modified so it can infect and multiply inside melanoma cells. Imlygic uses the melanoma cells’ own machinery to multiply, eventually overwhelming melanoma cells and killing them. Although Imlygic can enter healthy cells, it is not designed to multiply inside them.
Development of these products is challenging and linked to viral safety. Minimizing the viral replication of OVs in healthy cells is one of the main concerns in the first stages of clinical trials. Another aspect is the prevention of integration of the viral vector into the host genome. Vector design and engineering are therefore very important.
Conclusion
Oncolytic virotherapy offers promising therapy for cancer treatment. Do you need help with ATMP-related problems? Do not hesitate to contact our ATMP experts.
We are happy to help you with facility design, QC testing and regulatory advice during your oncolytic virus development process.
Get in touch with our experts
Should you want to discuss this more in-depth with one of our consultants, please do not hesitate to contact us.
References
- Oncolytic viruses for cancer immunotherapy | Journal of Hematology & Oncology | Full Text (biomedcentral.com)
- Frontiers | Oncolytic Virotherapy: From Bench to Bedside (frontiersin.org)
- Definition of oncolytic virus – NCI Dictionary of Cancer Terms – NCI
- Oncolytic viruses: a new class of immunotherapy drugs | Nature Reviews Drug Discovery
- ICH Considerations: Oncolytic Viruses (europa.eu)
- Frontiers | Delivery and Biosafety of Oncolytic Virotherapy (frontiersin.org)
- Frontiers | The Oncolytic Virus in Cancer Diagnosis and Treatment (frontiersin.org)
- Therapy with oncolytic viruses: progress and challenges | Nature Reviews Clinical Oncology
- CDC LC Quick Learn: Recognize the four Biosafety Levels
- 2017_11_22_guidelines_gmp_for_atmps_0.pdf (europa.eu)
- Oncolytic-virus-design.pdf (idt-biologika.de)
- Advances in oncolytic virotherapy | Communications Medicine (nature.com)
Stay ahead in life sciences
Keeping up with the fast-paced life sciences industry doesn’t have to be overwhelming.
Our newsletter delivers the latest insights, industry updates, and expert content directly to your inbox, helping you stay informed and make smarter decisions.
Discover more expert content
Webinar
From Strategy to First-in-Human: A Practical Roadmap for Biotech Development
Join our webinar to learn how to navigate nitrosamine risks and streamline your biotech development from early planning to first-in-human trials. Register now for expert insights.
Webinar
PMS & PMCF Compliance for Medical Devices Under EU MDR
Gain practical insights on PMS & PMCF compliance for medical devices under EU MDR. Watch our webinars on demand.
Case study
A Decade of Excellence: Linguistic Review Support for a Global Pharma Leader
QbD Group streamlines linguistic reviews for a leading pharma client, ensuring compliance and accuracy across 25 EU/EEA languages while meeting stringent regulatory deadlines.
Case study
Supporting Market Access to Essential Medicines in Europe
Support your entry into the European pharmaceutical market with expert regulatory guidance, ensuring compliance and access to essential medicines for patients. Contact us today for assistance.
%20Checklist.jpg)
Whitepaper
Medical Device Regulation (MDR) Checklist
Implement the Medical Device Regulation (MDR) with ease. Download our checklist of mandatory documents for MDR compliance.
Whitepaper
Regulatory Affairs for Pharma and Biotech
In this flyer, you will learn more about the regulatory services QbD Group provides for the pharmaceutical and biotechnology industries.
Whitepaper
Clinical Evaluation for Medical Devices under MDR
This whitepaper will guide you through crucial regulatory documents pertaining to the clinical evaluation process of your medical device. Download now!
Whitepaper
IVDR extension: what does this mean for you?
In this whitepaper, you will learn the impact of the IVDR transition extension and receive tips and strategies to navigate these regulatory changes.
Webinar
Drug-Device Combination Products and Article 117
Explore the regulatory complexities of Drug-Device Combination Products. Learn about Article 117 requirements, Notified Body Opinions, and more.
Whitepaper
Mobile health on the rise: exploring the regulatory landscape for reimbursement
This whitepaper will help you navigate the maze of the DTx regulatory environment, highlighting several important countries and regulations.
Whitepaper
Clinical investigations under MDR: key insights and practical experiences
This whitepaper covers clinical investigation authorization under MDR, the EU Legal Representative's role, and the MDR's impact on study conduct and post-market surveillance.
Case study
CE Mark Renewal for bioXtra Products: A Success Story
Discover how Lifestream Pharma successfully renewed the CE mark for their BioXtra Dry Mouth products under the EU MDR. Learn about the challenges faced, the approach taken for compliance, and the results achieved.
Webinar
Technical Documentation Essentials for Medical Device Software
Gain practical insights on crafting MDR-compliant technical documentation for Medical Device Software.
.jpg)
Webinar
Getting Started: Overcoming Initial Obstacles in Medical Device Software Development
Watch our webinar on demand and learn about regulatory obstacles, MDR, AI Act, and best practices for medical device software development and market entry.
Webinar
Mastering Clinical Performance Studies under IVDR
In the evolving regulatory landscape of IVDs, demonstrating clinical performance is more crucial and challenging than ever. Discover more in this webinar on demand.
Whitepaper
Clinical evidence for In Vitro Diagnostics under IVDR
In this whitepaper, we will guide you through the documents required for the demonstration of clinical evidence under the IVDR. Download now.
Webinar
Post-Market Surveillance Requirements for Medical Devices and IVDs
Learn about post-market surveillance requirements under MDR and IVDR regulations. Gain insights from industry experts in this on-demand webinar.
Whitepaper
The key role of Regulatory Affairs in the pharmaceutical industry: from drug development to commercialization
Discover the key role of Regulatory Affairs in pharma and how Regulatory Affairs teams support product lifecycle management in this whitepaper. Download now.
.jpg)
Webinar
3D Printing in the Healthcare World
Explore the challenges and opportunities of 3D printing in healthcare, featuring expert insights on regulations, pitfalls, and efficiency.
.jpg)
Webinar
IVDR Extension Explained: Tips & Strategies
Gain valuable insights on the IVDR extension and its impact on IVD manufacturers with our webinar on demand.
Whitepaper
Innovations in ATMP: state of the industry in 2024
This whitepaper explores the innovations in ATMP and solutions in detail, with a focus on the current landscape as of April 2024. Download now.
.jpg)
Case study
The journey toward IVDR compliance for the LVOne device
QbD Group helped Upfront Diagnostics gain entry into the MD/IVD industry by supporting them on their path to ISO 13485 certification.
Case study
Ensuring a smooth MDR transition for Oystershell's medical devices
The landscape of medical device regulations is constantly evolving, making it a challenge for companies to keep up. Our collaboration with Oystershell, which began in July 2023, highlights our expertise in transforming complex challenges into success stories, all with a touch of QbD Clinical magic.
Case study
Successful clinical evaluation supports rapid CE marking of Minze Health's Uroflowmeter
QbD Clinical assisted Minze Health, a urology-focused medical devices company, in obtaining CE marking under MDR through clinical evaluation.
.jpg)
Webinar
The Medical Device CE Certification Pathway Explained: From Classification to Conformity Assessment by the Notified Body
Learn about the Medical Device CE Certification Pathway, from classification to conformity assessment by a Notified Body. Join our webinar on demand.
.jpg)
Case study
Helping Relu to comply with changing regulations
QbD Group supported software company Relu with their expertise to comply with changing regulations.
.png)
Case study
Quickly bringing a new COVID-19 medical device to market
Obtaining the required government certifications for a medical device is always a challenge. Especially when the COVID clock is ticking.
Twitter Widget Iframe